National surveys: a way to manage treatment strategies in Parkinson’s disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease

Örjan Skogar1 Futurum Health Care Academy, Jönköping;2 Institution of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, StockholmCorrespondence[email protected]

Mats Nilsson1 Futurum Health Care Academy, Jönköping

Carl-Johan Törnhage3 Department of Pediatrics, Skaraborg Hospital, Skövde, Sweden

Johan Lökk2 Institution of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm

Pages 239-247 | Published online: 03 Jul 2013

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

MaetzlerWLiepeltIBergDProgression of Parkinson’s disease in the clinical phase: potential markersLancet Neurol20098121158117119909914
PubMed Web of Science ®Google Scholar
von CampenhausenSBornscheinBWickRPrevalence and incidence of Parkinson’s disease in EuropeEur Neuropsychopharmacol200515447349015963700
PubMed Web of Science ®Google Scholar
AlvesGMullerBHerlofsonKIncidence of Parkinson’s disease in Norway: the Norwegian ParkWest studyJ Neurol Neurosurg Psychiatry200980885185719246476
PubMed Web of Science ®Google Scholar
LinderJStenlundHForsgrenLIncidence of Parkinson’s disease and parkinsonism in northern Sweden: a population-based studyMov Disord201025334134820108376
PubMed Web of Science ®Google Scholar
FallPAAxelsonOFredrikssonMAge-standardized incidence and prevalence of Parkinson’s disease in a Swedish communityJ Clin Epidemiol19964966376418656224
PubMed Web of Science ®Google Scholar
Nordic Council of MinistersNordic Statistical YearbookCopenhagen, DenmarkNordic Council of Ministers2006
Google Scholar
AndenNECarlssonAKerstellJOral L-dopa treatment of parkinsonismActa Med Scand197018742472554911257
PubMedGoogle Scholar
RosaMMFerreiraJJCoelhoMFreireRSampaioCPrescribing patterns of antiparkinsonian agents in EuropeMov Disord20102581053106020222132
PubMed Web of Science ®Google Scholar
CohenJEHuman population: the next half centuryScience200330256481172117514615528
PubMed Web of Science ®Google Scholar
WinterYBalzer-GeldsetzerMvon CampenhausenSTrends in resource utilization for Parkinson’s disease in GermanyJ Neurol Sci20102941–2182220493500
PubMed Web of Science ®Google Scholar
LokkJCaregiver strain in Parkinson’s disease and the impact of disease durationEur J Phys Rehabil Med2008441394518385627
PubMed Web of Science ®Google Scholar
BaandersANHeijmansMJThe impact of chronic diseases: the partner’s perspectiveFam Community Health200730430531717873637
PubMed Web of Science ®Google Scholar
VossiusCGjerstadMBaasHLarsenJPDrug costs for patients with Parkinson’s disease in two different European countriesActa Neurol Scand2006113422823216542161
PubMed Web of Science ®Google Scholar
BainbridgeJLRuscinJMChallenges of treatment adherence in older patients with Parkinson’s diseaseDrugs Aging200926214515519220071
PubMed Web of Science ®Google Scholar
SvenssonEConstruction of a single global scale for multi-item assessments of the same variableStatist Med2001203831384616
PubMed Web of Science ®Google Scholar
SLD, Swedish pharmaceutical data, a part of IMS Health Available from: http://www.sld.fiAccessed January, 2011
Google Scholar
FolkhelseinstitutetRapport 2008: Reseptregisteret 2004–2007/Norwegian Prescription Database 2004–2007 Available from: http://www.norpd.no/Accessed January, 2011
Google Scholar
CalneDBSnowBJLeeCCriteria for diagnosing Parkinson’s diseaseAnn Neurol199232SupplS125S1271510370
PubMed Web of Science ®Google Scholar
RoosEKivelaKLahelmaE[Small changes in health differences in the Nordic countries during the 1980s and 1990s.]Lakartidningen2001982125762577 Swedish11433993
PubMedGoogle Scholar
DowdingCHShentonCLSalekSSA review of the health-related quality of life and economic impact of Parkinson’s diseaseDrugs Aging200623969372117020395
PubMed Web of Science ®Google Scholar
Norwegian Medical Association2011 Available from: http://www.legeforeningen.no/id/171362Accessed January, 2011 [Norwegian]
Google Scholar
Access to specialist doctors in Sweden. Welfare2007 Available from: http://www.socialstyrelsen.se/Lists/Artikelkatalog/Attachments/18153/2010-2011-1.pdfAccessed January, 2011 [Swedish]
Google Scholar
PechevisMClarkeCEViereggePEffects of dyskinesias in Parkinson’s disease on quality of life and health-related costs: a prospective European studyEur J Neurol2005121295696316324089
PubMed Web of Science ®Google Scholar
DodelRCEggertKMSingerMSEichhornTEPogarellOOertelWHCosts of drug treatment in Parkinson’s diseaseMov Disord19981322492549539337
PubMed Web of Science ®Google Scholar
PandyaMKubuCSGirouxMLParkinson disease: not just a movement disorderCleve Clin J Med2008751285686419088004
PubMed Web of Science ®Google Scholar
IMS Health Available from: http://www.imshealth.com/portal/site/imshealthAccessed January, 2011
Google Scholar
WatersCHSethiKDHauserRAMolhoEBertoniJMZydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled studyMov Disord200419442643215077240
PubMed Web of Science ®Google Scholar
OndoWGSethiKDKricorianGSelegiline orally disintegrating tablets in patients with Parkinson disease and “wearing off” symptomsClin Neuropharmacol200730529530017909308
PubMed Web of Science ®Google Scholar
LarsenJPBoasJErdalJEDoes selegiline modify the progression of early Parkinson’s disease? Results from a five-year study. The Norwegian-Danish Study GroupEur J Neurol19996553954710457386
PubMed Web of Science ®Google Scholar
GallagherDASchragAImpact of newer pharmacological treatments on quality of life in patients with Parkinson’s diseaseCNS Drugs200822756358618547126
PubMed Web of Science ®Google Scholar
BiglanKMSchwidSEberlySRasagiline improves quality of life in patients with early Parkinson’s diseaseMov Disord200621561662316450340
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

National surveys: a way to manage treatment strategies in Parkinson’s disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

National surveys: a way to manage treatment strategies in Parkinson’s disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date